Environment-mediated drug resistance: a major contributor to minimal residual disease

[1]  Charles P. Lin,et al.  RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. , 2009, Blood.

[2]  E. Estey,et al.  Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. , 2009, Blood.

[3]  T. Plesner,et al.  A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma , 2009, Hematological oncology.

[4]  T. Reiman,et al.  Altered Expression of Fibronectin and Collagens I and IV in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance , 2009, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[5]  R. Jove,et al.  Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. , 2009, Cancer research.

[6]  D. Stirewalt,et al.  Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. , 2009, Blood.

[7]  W. Berdel,et al.  Bortezomib, Dexamethasone, and Fibroblast Growth Factor Receptor 3–Specific Tyrosine Kinase Inhibitor in t(4;14) Myeloma , 2009, Clinical Cancer Research.

[8]  Izhak Haviv,et al.  Co-evolution of tumor cells and their microenvironment. , 2009, Trends in genetics : TIG.

[9]  T. Mikkelsen,et al.  Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  L. Staudt,et al.  Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.

[11]  Charles P. Lin,et al.  Rho-a and Rac-1 GTPases Play Major and Differential Roles in SDF1α- Induced Cell Adhesion and Chemotaxis in Multiple Myeloma. , 2008 .

[12]  D. Campana.  Status of minimal residual disease testing in childhood haematological malignancies , 2008, British journal of haematology.

[13]  T. Reiman,et al.  A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. , 2008, Blood.

[14]  Bin Jiang,et al.  Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. , 2008, The New England journal of medicine.

[15]  Mina J Bissell,et al.  Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. , 2008, Cancer research.

[16]  J. Thiery,et al.  Disseminated Tumor Cells of Breast Cancer Patients: A Strong Prognostic Factor for Distant and Local Relapse , 2008, Clinical Cancer Research.

[17]  W. Dalton,et al.  The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance , 2008, Clinical Cancer Research.

[18]  F. Pépin,et al.  Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.

[19]  A. Aboussekhra,et al.  Breast carcinoma-associated fibroblasts and their counterparts display neoplastic-specific changes. , 2008, Cancer research.

[20]  D. Kranz,et al.  Equilibrium between host and cancer caused by effector T cells killing tumor stroma. , 2008, Cancer research.

[21]  M. Mottolese,et al.  Induction of ErbB-3 Expression by α6β4 Integrin Contributes to Tamoxifen Resistance in ERβ1-Negative Breast Carcinomas , 2008, PloS one.

[22]  W. Dalton,et al.  Bone Marrow Stroma Confers Resistance to Apo2 Ligand/TRAIL in Multiple Myeloma in Part by Regulating c-FLIP1 , 2008, The Journal of Immunology.

[23]  T. Takayama,et al.  Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia , 2008, Leukemia.

[24]  G. Schuurhuis,et al.  Chemotherapeutic treatment of bone marrow stromal cells strongly affects their protective effect on acute myeloid leukemia cell survival , 2008, Leukemia & lymphoma.

[25]  D. Kuhn,et al.  Inhibition of Interleukin-6 Signaling with CNTO 328 Enhances the Activity of Bortezomib in Preclinical Models of Multiple Myeloma , 2007, Clinical Cancer Research.

[26]  Lidong Sun,et al.  Overexpression of integrin β1 inhibits proliferation of hepatocellular carcinoma cell SMMC‐7721 through preventing Skp2‐dependent degradation of p27 via PI3K pathway , 2007, Journal of cellular biochemistry.

[27]  G. Meinhardt,et al.  First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma , 2007, European journal of haematology.

[28]  J. Downing,et al.  A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. , 2007, Blood.

[29]  J. Heino,et al.  Increased gene expression levels of collagen receptor integrins are associated with decreased survival parameters in patients with advanced melanoma , 2007, Melanoma research.

[30]  R. Stupp,et al.  Integrin inhibitors reaching the clinic. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Robert A. Beckman,et al.  Phase I Evaluation of a Fully Human Anti–αv Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors , 2007, Clinical Cancer Research.

[32]  R. Weichselbaum,et al.  Induced sensitization of tumor stroma leads to eradication of established cancer by T cells , 2007, The Journal of experimental medicine.

[33]  Dan H. Moore,et al.  Increased β1 Integrin Is Associated with Decreased Survival in Invasive Breast Cancer , 2007 .

[34]  W. Dalton,et al.  β1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells , 2007, British journal of haematology.

[35]  W. Dalton,et al.  Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. , 2006, Blood.

[36]  J. Soulier,et al.  Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma , 2007, Leukemia.

[37]  Zhenfeng Duan,et al.  Signal Transducers and Activators of Transcription 3 Pathway Activation in Drug-Resistant Ovarian Cancer , 2006, Clinical Cancer Research.

[38]  Cheng Cheng,et al.  Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2. , 2006, Blood.

[39]  W. Muller,et al.  Addressing the Role of Cell Adhesion in Tumor Cell Dormancy , 2006, Cell cycle.

[40]  C. Streuli.  Faculty Opinions recommendation of Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. , 2006 .

[41]  D. Shaw,et al.  Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours , 2006, British Journal of Cancer.

[42]  M. Graf,et al.  Expression of MAC‐1 (CD11b) in acute myeloid leukemia (AML) is associated with an unfavorable prognosis , 2006, American journal of hematology.

[43]  H. Geinitz,et al.  β1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury , 2006, Oncogene.

[44]  C. Beam,et al.  Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells. , 2006, Cancer research.

[45]  Joe W Gray,et al.  Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. , 2006, Cancer research.

[46]  R. Rintoul,et al.  ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through β1 integrin-dependent activation of PI3-kinase , 2006, Cell Death and Differentiation.

[47]  L. Coussens,et al.  Tumor stroma and regulation of cancer development. , 2006, Annual review of pathology.

[48]  T. Sakai,et al.  Galectin-1 Interacts with the α5β1 Fibronectin Receptor to Restrict Carcinoma Cell Growth via Induction of p21 and p27* , 2005, Journal of Biological Chemistry.

[49]  Jens Eickhoff,et al.  Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion , 2005, Clinical Cancer Research.

[50]  Hirokazu Tamamura,et al.  Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. , 2005, Blood.

[51]  T. Fehm,et al.  A pooled analysis of bone marrow micrometastasis in breast cancer. , 2005, The New England journal of medicine.

[52]  J. Burger,et al.  CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells , 2005, Oncogene.

[53]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[54]  G. Schuurhuis,et al.  Minimal Residual Disease in Acute Myeloid Leukemia Is Predicted by an Apoptosis-Resistant Protein Profile at Diagnosis , 2005, Clinical Cancer Research.

[55]  Thomas Flohr,et al.  Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. , 2005, Blood.

[56]  J. Schouten,et al.  Gene expression profiling of minimal residual disease in acute myeloid leukaemia by novel multiplex-PCR-based method , 2004, Leukemia.

[57]  J. Kallen,et al.  Improved Lymphocyte Function-associated Antigen-1 (LFA-1) Inhibition by Statin Derivatives , 2004, Journal of Biological Chemistry.

[58]  Paul J. Williams,et al.  Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. , 2004, Blood.

[59]  G. Meinhardt,et al.  The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. , 2004, Blood.

[60]  J. Nesland,et al.  Isolated Tumor Cells in Bone Marrow Three Years after Diagnosis in Disease-Free Breast Cancer Patients Predict Unfavorable Clinical Outcome1 , 2004, Clinical Cancer Research.

[61]  W. Muller,et al.  Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. , 2004, Cancer cell.

[62]  G. Schuurhuis,et al.  MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia , 2004, Leukemia.

[63]  Rameen Beroukhim,et al.  Molecular characterization of the tumor microenvironment in breast cancer. , 2004, Cancer cell.

[64]  J. Ruidavets,et al.  Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. , 2004, Cancer research.

[65]  Yulia Nefedova,et al.  Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. , 2004, Blood.

[66]  K. Ohuchida,et al.  Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. , 2004, Cancer research.

[67]  H. Schreiber,et al.  Bystander elimination of antigen loss variants in established tumors , 2004, Nature Medicine.

[68]  J. Heino,et al.  Integrin chains beta1 and alphav as prognostic factors in human metastatic melanoma. , 2004, Melanoma research.

[69]  M. Wellner,et al.  Integrins and Cytokines Activate Nuclear Transcription Factor-κB in Human Neutrophils* , 2004, Journal of Biological Chemistry.

[70]  J. Heino,et al.  Integrin chains b1 and av as prognostic factors in human metastatic melanoma , 2004 .

[71]  Augusto Silva,et al.  Involvement of p53 in α4β1 integrin-mediated resistance of B-CLL cells to fludarabine , 2003 .

[72]  C. Beam,et al.  Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. , 2003, Cancer research.

[73]  M. Hansen,et al.  Ras GTPases: integrins' friends or foes? , 2003, Nature Reviews Molecular Cell Biology.

[74]  S. Goodison,et al.  Prolonged dormancy and site-specific growth potential of cancer cells spontaneously disseminated from nonmetastatic breast tumors as revealed by labeling with green fluorescent protein. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[75]  H. Kuroda,et al.  Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia , 2003, Nature Medicine.

[76]  W. Dalton,et al.  Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms , 2003, Leukemia.

[77]  W. Dalton,et al.  Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells , 2003, Oncogene.

[78]  Donald R Schwartz,et al.  Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. , 2003, Cancer cell.

[79]  W. Berdel,et al.  Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. , 2003, Blood.

[80]  J. Soria,et al.  Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells. , 2003, Cellular signalling.

[81]  T. Maeda,et al.  Statins augment vascular endothelial growth factor expression in osteoblastic cells via inhibition of protein prenylation. , 2003, Endocrinology.

[82]  P. Richardson,et al.  The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment , 2002, Cancer research.

[83]  H. Allgayer,et al.  Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  G. Naumov,et al.  Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. , 2002, Cancer research.

[85]  Y. Kameda,et al.  Increased expression of integrin beta1 is a poor prognostic factor in small-cell lung cancer. , 2002, Anticancer research.

[86]  W. Dalton,et al.  Adhesion-Mediated Intracellular Redistribution of c-Fas-Associated Death Domain-Like IL-1-Converting Enzyme-Like Inhibitory Protein-Long Confers Resistance to CD95-Induced Apoptosis in Hematopoietic Cancer Cell Lines1 , 2002, The Journal of Immunology.

[87]  Joerg Kallen,et al.  Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site , 2001, Nature Medicine.

[88]  F. Dammacco,et al.  Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. , 2001, Blood.

[89]  A. Hidalgo,et al.  Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. , 2001, Blood.

[90]  W. Dalton,et al.  Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR) , 2000, Oncogene.

[91]  K. Weinberg,et al.  Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[92]  W. Berdel,et al.  Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. , 2000, Blood.

[93]  H Sommer,et al.  Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  S. Harris,et al.  Stimulation of bone formation in vitro and in rodents by statins. , 1999, Science.

[95]  Christopher Haslett,et al.  Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo , 1999, Nature Medicine.

[96]  W. Dalton,et al.  Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines , 1999 .

[97]  G. Ciliberto,et al.  Blocking signaling through the gp130 receptor chain by interleukin‐6 and oncostatin M inhibits PC‐3 cell growth and sensitizes the tumor cells to etoposide and cisplatin‐mediated cytotoxicity , 1999, Cancer.

[98]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[99]  M. Brattain,et al.  Disruption of Fibronectin Binding to the α5β1 Integrin Stimulates the Expression of Cyclin-dependent Kinases and DNA Synthesis through Activation of Extracellular Signal-regulated Kinase* , 1998, The Journal of Biological Chemistry.

[100]  C. Larabell,et al.  Reversion of the Malignant Phenotype of Human Breast Cells in Three-Dimensional Culture and In Vivo by Integrin Blocking Antibodies , 1997, The Journal of cell biology.

[101]  R. Kerbel,et al.  Impact of the cyclin–dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents , 1996, Nature Medicine.

[102]  R. Kerbel,et al.  Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. , 1996, Journal of the National Cancer Institute.

[103]  R. Mannix,et al.  Integrin activation suppresses etoposide-induced DNA strand breakage in cultured murine tumor-derived endothelial cells. , 1996, Cancer research.

[104]  A. Morley,et al.  Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. , 1996, Blood.

[105]  J. Izbicki,et al.  Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. , 1993, Journal of the National Cancer Institute.

[106]  J. Trent,et al.  Development and characterization of a melphalan-resistant human multiple myeloma cell line. , 1991, Cancer research.

[107]  G. Giaccone,et al.  Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[108]  B. Teicher,et al.  Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. , 1990, Science.

[109]  Goldie Jh,et al.  Quantitative model for multiple levels of drug resistance in clinical tumors. , 1983 .

[110]  J. Goldie,et al.  Quantitative model for multiple levels of drug resistance in clinical tumors. , 1983, Cancer treatment reports.

[111]  Goldie Jh,et al.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979 .

[112]  J H Goldie,et al.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979, Cancer treatment reports.

[113]  J. Burchenal,et al.  Treatment of acute lymphoblastic leukemia. , 1972, Annual review of medicine.